Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc., shared a post on X:
“Recent publication of T-Bren on eBioMedicine – The Lancet Discovery Science:
Surprisingly, half-life (2.6 days) of T-Bren is relatively short compared to other topo1i trastuzumab ADCs! 
In our Annals of Oncology review we collected (see supplementary figure S6) available PK of trastuzumab-based ADCs with different drug-linkers compared to ‘naked’ trastuzumab!
To which Markus Eckstein, Senior Physician/Pathologist and Clinician Scientist at the University Hospital Erlangen, added:
“What does this short half life mean ? Is it rather a bad signal or maybe even good to avoid side effects?”
Title: A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody–drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours
Authors: Herui Yaoa, Ruihua Zhaob, Xiuping Laia, Qing Wenc, Meili Sunc, Ying Wanga, Suiwen Yea, Jun Jiad, Ling Guand, Yongqiang Zhange, Xian Wangf, Yahua Zhongg, Jianying Huangg, Mei Lih, Junlan Guoi, Fuguo Tianj, Yuan Yuank, Sa Xiaol, Hai Zhum, Yi Zhun, Rongbo Lino, Hong Zongb, Erwei Song
Title: Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
Authors: R. Colombo, S. D. Seredick, S. D. Barnscher, J. R. Rich
Other articles featuring Raffaele Colombo and Markus Eckstein on OncoDaily.